Helping Hands At Home, Inc in Van Nuys, California

Helping Hands At Home, Inc is a medicare-certified hospice facility in Van Nuys, California. It is a for profit hospice and this hospice is a Freestanding Hospice. It is located at 6710 Kester Ave, Suite 266 in Van Nuys, California. You can reach out to the office of Helping Hands At Home, Inc via phone at (818) 668-3427.

Helping Hands At Home, Inc is first approved in October, 2013 to provide medicare and/or medicaid services and its CMS certification number (CCN) is 751534. San Francisco is the CMS Regional Office responsible for the certification of this hospice.

Contact Information


Helping Hands At Home, Inc
6710 Kester Ave, Suite 266, Van Nuys, CA, 91405
(818) 668-3427

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago

Map and Direction



Hospice Profile

NameHelping Hands At Home, Inc
Location6710 Kester Ave, Suite 266, Van Nuys, California
Hospice ID751534
CategoryFreestanding Hospice
Ownership TypeProprietary - Corporation
Profit TypeFOR PROFIT
Accreditation ProviderThe Joint Commission (TJC)
SSA county code200

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago

NPI associated with this Hospice

A hospice usually have one NPI number but sometimes it may have multiple NPI numbers. We have found possible NPI number/s associated with Helping Hands At Home, Inc from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1629377437
Organization NameHelping Hands At Home Inc
Address6710 Kester Ave Van Nuys, California, 91405
Phone Number(818)787-0660

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago


Quality of Patient Care at Helping Hands At Home, Inc

Hospice staff should discuss treatment preferences and patient beliefs and values with patients and/or caregivers. They should also identify and provide interventions to address pain, shortness of breath and constipation (caused by opioids) to improve patient comfort and quality of life. Helping Hands At Home, Inc has the following score in these measures of patient care.
Better than National Average Worse than National Average

Quality MeasureProvider ScoreNational Score
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice careNot Available98.3
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice careNot Available93.6
Patients who were checked for pain at the beginning of hospice careNot Available93.9
Patients who got a timely and thorough pain assessment when pain was identified as a problemNot Available77.7
Patients who were checked for shortness of breath at the beginning of hospice careNot Available97.3
Patients who got timely treatment for shortness of breathNot Available94.6
Patients taking opioid pain medication who were offered care for constipationNot Available93.3

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago


Services Provided by Helping Hands At Home, Inc:

Hospice provide various services either through their own staff or through third-party arrangements. Find the list of services provided by Helping Hands At Home, Inc below:
  • By staff
    • Home Health Aide Service
    • Counseling Service
    • Medical Social Service
    • Nursing Service
    • Physician Service

  • Under Arrangement
    • Home Maker Service
    • Medical Supply Service
    • Occupational Therapy
    • Physical Therapy
    • Short Term Inpatient care
    • Speech Pathology

  • Combination of Staff and Under Arrangement
    • No services

  • Type of Short Term Inpatient Care
    • Acute and Respite

Number of Full-time equivalent Employees:

Number of full time equivalent employees at Helping Hands At Home, Inc
Home Health Aides1
Counselors1
Licensed Practical or Vocational Nurses1
Medical Social Workers 1
Physicians1
Registered Nurses1
Total Employees6

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago


Number of Full-time equivalent Volunteers:

Others1
Total Volunteers1

News Archive

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Drugs targeting T cells may be effective in treating cerebral malaria

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children.

Study identifies existence of an antitumor molecule that originates within SMYD3 oncogene

A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or tumour suppressor genes. Normally both categories of anticancer and procancer genes are in different regions of our chromosomes.

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Scientists develop new way to see brain cells talk, shedding light on neurological diseases

Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.

Read more Medical News

› Verified 8 days ago

Certification Details for Helping Hands At Home, Inc:

  • October, 2013 is the initial visit of the health survey for certifications by CMS.
  • It is in compliance at the time of certification survey by CMS.
  • It is in compliance with CMS program requirements based on an acceptable plan for correction of deficiencies.
  • It is eligible to participate in the medicare and/or medicaid program.
  • National Government Services is the Medicare Administrative Contractor (MAC), intermediary or carrier servicing this hospice.
  • Current status is Active Provider.
  • Reason of certification is Initial.
  • End of fiscal year is on 31, December.

Hospices in Van Nuys

Haga Hospice, Inc
Location: 5627 Sepulveda Blvd., Suite 230, Van Nuys, California, 91411
Phone: (818) 668-3427
West Coast Hospice Management, Inc.
Location: 13746 Victory Blvd., Ste. 301, Van Nuys, California, 91401
Phone: (818) 668-3427
Helping Hands Hospice Services
Location: 7136 Haskell Avenue, Suite 302, Van Nuys, California, 91406
Phone: (818) 668-3427
Heaven Hospice, Inc
Location: 14557 Friar St, Ste B1, Van Nuys, California, 91411
Phone: (818) 668-3427

Medicare Hospice Care

What is Hospice Care?
Hospice care is a type of care and philosophy of care that focuses on the palliation of a chronically ill, terminally ill or seriously ill patient's pain and symptoms, and attending to their emotional and spiritual needs. Care may be provided in a patient's home or in a designated facility such as nursing home, hospital unit or freestanding hospice, with level of care and sometimes location based upon frequent evaluation of the paients needs. The four primary levels of care provided by hospice are routine home care, continuous care, general inpatient and respite care.

How long can one get medicare hospice care?
Hospice care is for people with a life expectancy of 6 months or less (if the disease runs its normal course). If the person receiving hospice care live longer than 6 months, he or she can still get hospice care.
  • A person can get hospice care for two 90-day benefit periods, followed by an unlimited number of 60-day benefit periods.
  • At the start of each period, the hospice medical director or other hospice doctor must recertify that the person is terminally ill (with a life expectancy of 6 months or less). This step is must for continued hospice care.

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.